Literature DB >> 17654751

Genomic variants of TLR1--it takes (TLR-)two to tango.

Ralf R Schumann1, Richard I Tapping.   

Abstract

Toll-like receptors (TLR) are innate immune sensors of microbial cell wall products that initiate early host responses. The TLR2 receptor complex has been shown to contain heterodimers of TLR2 with either TLR1 or TLR6 enabling the host to detect different microbial molecules, such as lipopeptides of different chemical composition. In this issue of the European Journal of Immunology, an important role in the sensing of microbial products for I602S, a single nucleotide polymorphism (SNP) in human TLR1 has been identified. This result, in combination with another recently published report on this polymorphism elucidating a functional role in cell trafficking (surface expression of the receptor complex in individuals carrying the SNP was altered), provide genetic evidence affirming the important function of TLR1 as an essential co-receptor for TLR2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17654751     DOI: 10.1002/eji.200737604

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  Cell surface trafficking of TLR1 is differentially regulated by the chaperones PRAT4A and PRAT4B.

Authors:  Bryan E Hart; Richard I Tapping
Journal:  J Biol Chem       Date:  2012-03-23       Impact factor: 5.157

2.  Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease.

Authors:  Joseph M Reynolds; Bhanu P Pappu; Juan Peng; Gustavo J Martinez; Yongliang Zhang; Yeonseok Chung; Li Ma; Xuexian O Yang; Roza I Nurieva; Qiang Tian; Chen Dong
Journal:  Immunity       Date:  2010-04-29       Impact factor: 31.745

3.  The expression and function of Nod-like receptors in neutrophils.

Authors:  Anna-Karin Ekman; Lars Olaf Cardell
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

4.  Differential trafficking of TLR1 I602S underlies host protection against pathogenic mycobacteria.

Authors:  Bryan E Hart; Richard I Tapping
Journal:  J Immunol       Date:  2012-10-26       Impact factor: 5.422

5.  A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling.

Authors:  Kamalpreet Nagpal; Theo S Plantinga; Joyce Wong; Brian G Monks; Nicholas J Gay; Mihai G Netea; Katherine A Fitzgerald; Douglas T Golenbock
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

6.  Genetic and Metabolic Signals during Acute Enteric Bacterial Infection Alter the Microbiota and Drive Progression to Chronic Inflammatory Disease.

Authors:  Karishma Kamdar; Samira Khakpour; Jingyu Chen; Vanessa Leone; Jennifer Brulc; Thomas Mangatu; Dionysios A Antonopoulos; Eugene B Chang; Stacy A Kahn; Barbara S Kirschner; Glenn Young; R William DePaolo
Journal:  Cell Host Microbe       Date:  2016-01-13       Impact factor: 21.023

7.  Novel mutations in TLR genes cause hyporesponsiveness to Mycobacterium avium subsp. paratuberculosis infection.

Authors:  Mangesh R Bhide; Rastislav Mucha; Ivan Mikula; Lucia Kisova; Rostislav Skrabana; Michal Novak; Ivan Mikula
Journal:  BMC Genet       Date:  2009-05-26       Impact factor: 2.797

8.  Effects of human Toll-like receptor 1 polymorphisms on ageing.

Authors:  Peter Uciechowski; Eva Maria Oellig; Erminia Mariani; Marco Malavolta; Eugenio Mocchegiani; Lothar Rink
Journal:  Immun Ageing       Date:  2013-02-07       Impact factor: 6.400

9.  STAT2*C related genotypes and allele but not TLR4 and CD40 gene polymorphisms are associated with higher susceptibility for asthma.

Authors:  Yao-Yuan Hsieh; Lei Wan; Chi-Chen Chang; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  Int J Biol Sci       Date:  2009-01-09       Impact factor: 6.580

10.  Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease.

Authors:  Xin Ma; Yuhua Liu; Brian B Gowen; Edward A Graviss; Andrew G Clark; James M Musser
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.